YD Bio Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of January 2026 for YD Bio Ltd, a foreign private issuer headquartered in Taipei, Taiwan. The report details corporate governance updates and regulatory compliance status as of January 21, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on non-financial corporate governance matters.
Material Changes
- Board Appointments: On January 16, 2026, the Board appointed Dr. Chang as Chairman of the Compensation Committee and a member of the Audit and Nominating and Corporate Governance Committees.
- Board Appointments: On January 16, 2026, the Board appointed Dr. Lu as Chairman of the Nominating and Corporate Governance Committee and a member of the Audit and Compensation Committees.
- Compliance Status: On January 20, 2026, the Company notified Nasdaq that it has regained compliance with Nasdaq Listing Rule 5605 regarding Audit Committee requirements and is no longer subject to a cure period.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies were disclosed in this document, other than the prior non-compliance with Nasdaq listing rules which has now been resolved.
Investor Verification Checklist
- Verify the full biographies and qualifications of Dr. Chang and Dr. Lu to assess their impact on board oversight.
- Confirm the specific details of the prior Audit Committee non-compliance that necessitated the cure period.
- Review subsequent filings for any financial updates, as this 6-K contains no financial data.